Specialty Guideline Management Taltz
Customize your policy alerts
Sign up for cvs_caremark Policy 2013-A alerts
Get alerted when Policy 2013-A changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and continuation coverage for Taltz (ixekizumab) used to treat moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It applies to members seeking initial or renewal authorization and establishes clinical criteria, documentation, prescriber specialty, and safety requirements.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.